Pyridazinone compounds of Formula (I) including stereoisomers tautomers and pharmaceutically acceptable salts thereof useful for inhibiting Btk kinase and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula (I) for in vitro in situ and in vivo diagnosis and treatment of such disorders in mammalian cells or associated pathological conditions are disclosed.
